samedan logo

 
 
spacer
home > pmps > autumn 2003 > isomalt as excipient in pharmaceuticals
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Isomalt as Excipient in Pharmaceuticals

Well known as a sugar replacer in the food industry, isomalt is also highly suitable for a wide range of pharmaceutical applications.

Pharmaceutical products must meet increasingly exacting requirements; it is not enough for a medication to have the desired effect. Products also require optimal quality in taste, texture, appearance, shelf life and packaging. This applies all the more to the highly competitive market of OTC products and dietary supplements.

The excipient also plays a key role in pharmaceutical products. It must provide the perfect means of delivery for the actual active ingredient while giving the product ideal characteristics. The main requirements are compatibility, stability in terms of physiological and chemical properties (non-ageing), neutrality in taste and appearance, and the ability to enable precise dosage. Furthermore, good organoleptic properties and added benefits like calorie reduction, tooth-friendliness or low glycemic response are important, especially where consumers or patients can choose between different products with comparable effect. Generally speaking for pharmaceutical manufacturers, the safety and availability of the excipient is crucial.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ines Kranczoch, Manager of Special Projects and Pharma Projects, Technical Services at Palatinit GmbH, and Tillmann T Dörr, Product Manager at Südzucker

Ines Kranczoch is Manager of Special Projects and Pharma Projects, Technical Services at Palatinit GmbH in Germany. She attended the University of Applied Sciences in Berlin and graduated as an Engineer in Food Technology in 1994. Her diploma thesis was on the implementation of a quality system in accordance of DIN ISO 2001 in a confectionery company. From 1994-1998, Ms Kranczoch worked in the Technical Service of Polyolefin Catalysts and Statistical Process and Quality Control departments for Grace GmbH, before moving on to Palatinit GmbH in 1998 as Technical Services Area Manager for Eastern Europe


Tillmann T Dörr is currently Product Manager for the development of pharma excipients made from sugars and polyols at Südzucker, where he has worked for over eight years. His previous experience includes Project Manager for liquid sugar and pasty sugars and product development with isomalt in confectionery, and Product Manager for formulation and process development of crystalline sugar products and polyols for food and non-food application. Mr Dörr gained his degree in Food Technology and Engineering in 1994.


spacer
Ines Kranczoch
spacer
spacer
spacer
Tillmann T Dörr
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Everything Genetic launches Next Generation Sequencing service as part of its public-private partnership with Berkshire and Surrey Pathology Services

NANTWICH, CHESHIRE and GUILDFORD, SURREY, NOVEMBER 2022. Everything Genetic, a fast-growing UK business offering genetic testing services for the diagnosis, prevention and treatment of a range of cancers, has partnered with Berkshire and Surrey Pathology Services (BSPS), an NHS Pathology Network, to provide Next Generation Sequencing (NGS) services to healthcare professionals and customers across the UK.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement